Search Results for "ATTR"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

HELIOS-B: Primary results from a phase 3 study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy

Effect of Patisiran Treatment in Patients with hATTR Amyloidosis with Cardiomyopathy and Polyneuropathy: Post-hoc Analysis of the APOLLO-B Study

Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis

Holistic clinical management of ATTR amyloidosis with cardiomyopathy

Efficacy and Safety of Vutrisiran in ATTR-CM Across the Spectrum of Age

Baseline Characteristics of Patients with ATTR Amyloidosis Enrolled into the ConTTRibute Registry

Clinician preferences for transthyretin amyloidosis treatment: Results from a discrete-choice experiment

Patisiran Treatment for ATTR Cardiac Amyloidosis: 18-Month Results of the Phase 3 APOLLO-B Study

Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

ATTR-CM HELIOS-B Data Summary

ATTR-CM HELIOS-B Data Summary deck provides a comprehensive overview of the HELIOS-B results. Also includes information on ATTR-CM and the MOA of RNAi therapeutics.

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.